We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Amgen Fears 'Staggering Loss' After FDA Exclusivity Denial

Law360 (February 23, 2018, 8:06 PM EST) -- Amgen Inc. urged the D.C. Circuit on Friday to quickly block generic versions of its lucrative calcium-control drug Sensipar, saying it faces a “staggering loss” of sales because the U.S. Food and Drug Administration unfairly withheld exclusivity rights.

The drugmaker’s emergency motion came shortly after a D.C. federal judge upheld the FDA’s denial of pediatric exclusivity, which would have kept generics at bay for an extra six months. Amgen, which earned nearly $1.4 billion from U.S. sales of Sensipar last year, wants an injunction pending appeal of...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Amgen Inc. v. Alex Azar, II, et al


Case Number

18-5046

Court

Appellate - DC Circuit

Nature of Suit

2890 Other Statutory Actions

Date Filed

February 21, 2018

Law Firms

Companies

Government Agencies

Judge Analytics

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.